Background: The TNFRSF14 (herpes virus entry mediator (HVEM)) delivers a negative signal to T cells through the B and T Lymphocyte Attenuator (BTLA) molecule and has been associated to a worse prognosis in various malignancies. Here, we investigated whether HVEM might represent a novel target for cancer immunotherapy.
therapeutic effect of the mAb was lost with the tumor deficient for HVEM, showing that HVEM expression by the tumor was necessary for the therapeutic effect. Accordingly, no agonist activity of the mAb was detected on human T cells in vivo. Surprisingly, we observe a similar albeit milder effect of the antibody on tumor growth in nonhumanized NSG mice that is also lost with the HVEM-deficient cell line. However, in vitro analyses show that the antibody alone has no significant impact on tumor survival per se. In contrast, addition of peritoneal macrophages from NSG mice to the culture results in higher mortality of the tumor, suggesting that myeloid cells of NSG mice might participate in tumor control in vivo. Finally, we reproduce the in vivo antitumor effect of the antibody with an HVEM-positive human melanoma cell line, but not with an HVEM-negative human breast cancer cell line, suggesting that the therapy could be applied to various HVEM-positive cancers, independently of their tissue origin.
Conclusion: Our results show that HVEM/BTLA is a novel immune checkpoint and that a mAb targeting HVEM might be a promising strategy for cancer immunotherapy. 
Background
Immune escape by tumor is now considered a hallmark of cancer (1) . Many immune mechanisms are involved to explain loss of tumor control, including defective MHC function and expression, recruitment of suppressive immune cells or expression of coinhibitory receptors such as PD-L1 (2) . In the last few years, targeting co-inhibitory molecules (that can be expressed by tumor or immune cells) with antibodies showed impressive results in tumor regression and overall survival, leading to approval of anti-CTLA-4, anti-PD-1 and anti-PD-L1 in numerous cancers (3). However, the success of immune checkpoint inhibitors (ICI) is still partial and many patients fail to respond.
Limited tumor infiltrate (cold tumors) or low expression of the targeted molecule may explain the relative inefficiency of ICI (4, 5) . To overcome these limitations, it is necessary to explore other pathways that might be involved in immune escape and that could complement actual therapies.
Recently, a new co-inhibitory pair has been highlighted in anti-tumor immune response: HVEM (Herpes Virus Entry Mediator, TNFRSF14) and BTLA (B and T lymphocyte attenuator). These two molecules can be expressed by many immune cells including T-cells, in which signaling through BTLA is associated to inhibition of their activation (6, 7) . Additionally, the HVEM network includes many additional partners, such as LIGHT, lymphotoxin α (LTα) or CD160 (8) . Like BTLA, binding of HVEM to CD160 on T-cells is associated with an inhibition of their activation (9) . On the other side, stimulation of HVEM on T-cells by any of its ligands is associated with proliferation, survival and inflammatory cytokines production, such as IL-2 and IFN-γ (9, 10) . Several clinical studies have shown that HVEM expression is upregulated in many types of cancers including colorectal cancers (11) , esophageal carcinomas (12), gastric cancers (13) , hepatocarcinomas (14) , breast cancers (15) or lymphomas (16) .
In these studies, high level of HVEM expression by tumors was associated with worse prognosis and lower survival. Moreover, HVEM expression by tumors was also associated with a reduction of CD4 and CD8 tumor-infiltrating lymphocytes (TIL) numbers (11, 12, 14) .
Few studies considered affecting tumor growth by targeting the HVEM network. In fact, strategies to inhibit HVEM expression by tumors, by competing for its ligands or directly stimulating HVEM expressed on T-cells, lead to increased T cell proliferation and function in syngeneic mouse models (12, (17) (18) (19) . However, to our knowledge, no study so far has assessed the possibility to use a monoclonal antibody (mAb) to HVEM to favor the anti-tumor immune response and a fortiori in a humanized context in vivo.
Herein, we explored the possibility that HVEM/BTLA might represent a novel immune checkpoint during anti-tumor immunity and investigate the therapeutic potential of a murine antibody targeting human HVEM in humanized mice models grafted with various human tumor cell lines, which express HVEM or engineered not to express HVEM by CRISPR/Cas9. To generate humanized mice, we used immuno-compromised NOD.SCID.γc null (NSG) mice which are deprived of murine T-, B-and NK-cells but that retain functionally immature macrophages and multinucleated cells (20) . We reconstituted these mice with human PBMC, allowing the effect of blocking HVEM to be studied on both tumors, murine myeloid cells and human T-cells. Our results indicate that HVEM/BTLA is a novel immune checkpoint that can be targeted with an anti-HVEM mAb, a potential useful strategy for cancer immunotherapy of HVEM + tumors.
Methods

Preparation of human peripheral mononuclear cells
Human peripheral blood mononuclear cells were isolated on a Ficoll gradient (Biocoll).
Cells were washed in PBS 3% FCS and diluted at the appropriate concentration in 1× PBS before injection into mice.
Humanized mice tumor model
All animals used were NSG mice (stock ≠005557) purchased from the Jackson laboratory (USA). To assess therapeutic activity, 8-20-week-old NSG mice (males and females) were injected subcutaneously with 2.10 6 tumour cells. One week later, mice were irradiated (2 Gy) and engrafted the same day with 2.10 6 huPBMC by retro orbital injection. 4-5 days after transplantation, the anti-huHVEM antibody or isotype control was injected intraperitoneally at 2 mg/kg. General state, body weight and survival of mice were monitored every 3-4 days to evaluate Graft-vs-Host-Disease (GVHD) progression. Mice were euthanized when exhibiting signs of GVHD, such as hunched back, ruffled fur, and reduced mobility.
Antibodies
The clone 18.10 has been described previously (21) . Briefly, 18.10 is a murine IgG1 anti-human HVEM mAb and was produced as ascites and purified by protein A binding and elution with the Affi-gel Protein A MAPS II Kit (Bio-rad). Mouse IgG1 isotype control (MOPC-21 clone) was purchased from Bio X Cell (West Lebanon, NH, USA). amplified with the following primers: TGCGAAGTTCCCACTCTCTG (Forward) and GGATAAGGGTCAGTCGCCAA (Reverse). Cells were cloned by limiting dilution in 96-well plates. Clones were screened for HVEM expression by flow cytometry using anti-HVEM (clone 94801, BD) and were considered as negative if HVEM expression was undetectable for at least 3 subsequent measurements.
In vitro assays
PC3 cells were seeded in 96-wells plate at 7000 cells/well in RPMI medium.
Macrophages from NSG mice were obtained by peritoneal wash. The target to effector ratio was 1:10 for cell death evaluation and 1:5 for apoptosis monitoring. Cells were treated by the anti HVEM antibody or its isotype control MOPC21 at 10µg/ml. 
Results
HVEM is an immune checkpoint during anti-tumor T cell immune response
To investigate whether HVEM might behave as an immune checkpoint for tumor control in humanized mice, we generated an HVEM-deficient cell line derived from HVEM-expressing PC3 cell line using CRISPR-Cas9 technology ( Fig 1A) . Transfection of CRISPR-Cas9/sgRNA complex resulted in 30% of cleavage efficiency, corresponding to 4% of cells affected on two alleles ( Figure S1A ). After subcloning, we obtained several clones with prolonged undetectable surface expression of HVEM ( Figure S1B ). We picked the clone 1B11 for further experiments given its morphological similarity with wild-type PC3 ( Figure S1C ). Although both cell lines grew similarly in non-humanized NSG mice, there was a marked difference in tumor growth in PBMC-reconstituted mice:
HVEM-deficient PC3 1B11 grew slower compared to wild type PC3, demonstrating that HVEM acted like an immune checkpoint blocker in this model ( Figure 1B ).
Anti-HVEM treatment is associated to a reduction in tumor growth and an increase in TIL number and proliferation that depend on HVEM expression by the tumor
Having demonstrated that HVEM was an immune checkpoint for anti tumor immunity, we wanted to evaluate whether HVEM could be targeted for therapy by a monoclonal antibody. Thus, NSG mice were grafted s.c with parental PC3 or the HVEM-deficient 1B11 clone, injected with PBMCs from healthy donors 7 to 8 days after and treated weekly with 2mg/kg of the 18.10 anti-HVEM mAb. Tumor growth was significantly reduced in mice treated with the 18.10 mAb compared to isotype-treated controls, an effect that could already be observed after a single injection (Figure 2A) . Flow cytometry analysis of human tumor-infiltrating lymphocytes (TIL) revealed an increase in CD4 T-cells numbers and a similar tendency for CD8 T-cells ( Figure 2B ). Additionally, frequencies of cells expressing the proliferation marker Ki67 were significantly elevated in both CD4 and CD8 T-cells ( Figures 2C) . However, the treatment with the anti-HVEM mAb was ineffective at controlling the growth of 1B11 in humanized mice ( Figure 2D ), indicating an essential role for HVEM expressed by the tumor in treatment efficacy. Accordingly, no difference in TIL numbers ( Figure 2E ) or frequencies of Ki-67 + T cells ( Figure 2F ) could be detected with the HVEM-deficient PC3 cell line. Overall, anti-HVEM therapy in humanized mice decreased the growth of the PC3 cell line, associated to an increase in TIL numbers and proliferation that depend on HVEM expression by the tumor.
The mAb has no direct effect on human T cells in vivo
We monitored HVEM expression by human PBMC and confirmed that HVEM was highly expressed by human T and B cells before injection into mice ( Figure 3A) . Thus, the data described above could be explained in part by activation of the HVEM signaling pathway, leading to improved proliferation and functions of human T cells in vivo.
Several lines of evidence argue against this hypothesis. First, the number and proliferation status of TIL was not affected by the treatment in the absence of tumor control ( Fig 2C-D) . Second, Graft-vs-Host Disease (GVHD) that occurs in immunocompromised mice grafted with human T cells, was not affected by the treatment as documented by similar weight loss and survival in the experimental groups ( Fig 3B) .
Third, similar numbers and frequencies of Ki67 + cells were observed in the spleens of mice of HVEM-treated or control groups (Figures 3C) . Altogether, these results show that the mAb has no effect on human T cells in vivo, at least in this humanized mice model.
NSG myeloid cells are able to kill wild-type PC3 cells in presence of anti-
HVEM antibody
Knowing that HVEM expression by the tumor was crucial for the efficacy of the mAb, and that it had no direct impact on human T cells in vivo, we evaluated whether the mAb would be able to mediate killing of tumor cells. To that end, we engrafted PC3 wild-type and clone 1B11 in non-humanized NSG mice and monitored tumor growth following mAb administration. Interestingly, a significant reduction in tumor growth was observed for wild-type PC3 ( Figure 4A ). In contrast, no difference in tumor growth was observed for the clone 1B11 with anti-HVEM therapy ( Figure 4B ). Thus, the mAb had a mild toxic effect on the cell line in the absence of human T cells, suggesting a direct effect mediated by HVEM signaling on the tumor. However, in vitro assays showed that the anti-HVEM mAb was unable to induce tumor cell death by itself ( Figure 4C ). Because NSG mice are on a NOD genetic background which is deficient for complement activity (20) , we surmised that innate immunity of NSG mice might be involved in the activity of the mAb. To assess the participation of myeloid cells in the anti-tumor response, we injected the anti-Gr1 mAb during the anti-HVEM treatment to deplete neutrophils and macrophages of NSG mice. There was a trend for an abolition of the effect of the HVEM mAb in anti-Gr1-treated mice compared to controls ( Figure   S2C ), suggesting that Gr1 + cells might participate in tumor control following treatment. However, NSG mice treated with anti-Gr1 rapidly suffered weight loss and died ( Figure S2A-B) , obscuring the interpretations of these experiments. To bypass this difficulty, we cultured PC3 cells with peritoneal cells from NSG mice, which were mostly macrophages ( Figure S3 ). This resulted in an increased proportion of apoptotic cells in the culture in presence of the anti-HVEM mAb, using live imaging ( Figure 3D ).
Furthermore, examination of video microscopy of the co-cultures revealed that tumor cells were killed by contact with NSG peritoneal macrophages with no evidence for engulfment of tumor cells (Video S1). Altogether, these results show that NSG peritoneal macrophages were able to kill HVEM-expressing tumor cells in presence of the anti-HVEM mAb by a cell-contact dependent mechanism.
Anti-HVEM anti-tumor effect in melanoma but not triple-negative breast cancer in humanized mice
In light of the effect of the anti-HVEM mAb on PC3 tumor growth, we sought to determine whether this observation could be extrapolated to other type of tumors. No difference in tumor growth were observed with mice grafted with the triple-negative breast cancer cell line MDA-MB-231, which does not express HVEM ( Figure 5A-B) . In contrast, a significant reduction of tumor growth was observed in mice grafted with the HVEM-positive Gerlach melanoma cell line ( Figure 5C-D) , similar to the PC3 cell line. Thus, therapeutic efficacy of the anti-HVEM mAb was heavily dependent on the expression of HVEM by the tumor rather than by the tissue origin of the tumor.
Discussion
Here, we report for the first time that HVEM is a novel immune checkpoint during anti- promote tumor cell death directly, as it has been reported that in some circumstances HVEM signaling may induce apoptosis (22) , and (iv) immunogenic tumor cell death may be caused by FcR-dependent mechanisms elicited by murine myeloid cells (23) .
Here, we have tested these hypotheses and found that the mAb was unable to directly activate human T cells, as judged by similar frequencies of Ki67 + cells and GVHD occurrence in anti-HVEM treated mice relative to controls. Furthermore, we show that HVEM expression by the tumor was necessary to elicit tumor control by the mAb.
However, we did not observe increased tumor killing in vitro in presence of the mAb relative to isotype control, indicating that direct killing in vivo might not be the chief mechanism that can explain tumor control by the mAb. Surprisingly, we identified myeloid cells of NSG mice as key players in the mode of action of the mAb, confirming published observations in syngeneic mouse models that myeloid cells are crucial for tumor control upon immune checkpoints inhibitors treatment (24) (25) (26) . NSG mice have no T-cells, no B-cells, no NK-cells owing to the SCID and γc mutations, and no complement and defectives DC and macrophages owing to the NOD genetic background (27) . Here, we showed that killing of tumor cells by peritoneal macrophages from NSG mice was enhanced in presence of the anti-HVEM mAb, providing a possible mechanism to explain better control of tumor growth in vivo with or without human T cells. Because of the murine nature of the mAb, binding to murine Fc-receptors present on myeloid cells of NSG might have propelled the therapeutic efficacy of the mAb. In our setting, we used IgG1, that is reported to bind to CD16 (FcgRIII) and CD32 (FcgRIIB), activating and inhibitory receptors, respectively (28) .
However, NOD background has been associated with a strong decrease in FcgRIIB expression by macrophages (29) . Consequently, activating FcgRIII might be the main receptor involved in FcR-dependent activity of murine myeloid cells in NSG mice.
Several possibilities exist to explain tumor killing by myeloid cells, through antibodydependent cellular phagocytosis (ADCP), local secretion of cytokines or free radicals, expression of FasL that would target Fas expressed by tumor cells and many others (30, 31) . We did not see evidence for ADCP on the video microscopies collected during the course of this study, which rather indicated that cell killing was mediated by cell contact. The exact mechanism by which myeloid cells killed the tumor in presence of the mAb remains to be elucidated.
An important observation that we made using CRISPR/Cas9 abolition of HVEM expression, was that the expression of HVEM by the tumor was strictly required for therapeutic efficacy. Thus, one can infer that HVEM expression by human cells play little or no role in our model. In contrast, Park et al. showed in a syngeneic mouse model that transfecting an agonist scFv anti-HVEM on tumors cells resulted in an increase in T-cell proliferation, as well as improved IFN-γ and IL-2 production and better tumor control (18) . This discrepancy could be explained by the fact that T-cells are strongly activated in huPBMC mice (32) . Since HVEM is downregulated upon activation (33) , it may have limited binding of anti-HVEM antibody on T-cells in our model. Thus, it remains possible that the mAb is still endowed with agonist properties in vitro or that it would behave differently in another model or in humans. On the other side, BTLA is also upregulated upon T-cell activation (33) , so the anti-HVEM mAb might also have limited inhibition of activated T-cells through inhibition of the HVEM-BTLA axis. Indeed, we observed improved rejection of the HVEM-deficient tumor by human T cells relative to the wild type tumor, indicating that the HVEM/BTLA signaling is inhibitory for anti-tumor immunity in humanized mice. Likewise, previous studies in mice showed that inhibiting HVEM expression on the tumor or its interaction with its ligands has a positive effect on T cells. Injection of a plasmid encoding a soluble form of BTLA (to compete with endogenous BTLA for HVEM) was associated with an increase inflammatory cytokines production by TIL and a decrease in antiinflammatory cytokines at the RNA level (17) . Moreover, silencing of tumor HVEM with siRNA was also associated with an increase in CD8 T cells and inflammatory cytokine production in a murine colon carcinoma model (12) . In addition, use of siRNA to HVEM on ovarian cancer in vitro promote T-cells proliferation and TNF-α and IFN-γ (19) . Thus, our data suggest the following model to explain the anti-tumor activity of our anti-HVEM antibody in NSG mice: binding of the mAb on HVEM expressed by the tumor would activate tumor killing by murine myeloid cells, which together with blockade of the HVEM inhibitory network would enhance proliferation and functions of human Tcells to kill tumor cells.
Scheduled treatment with an anti-human HVEM mAb in humanized mice exerted a potent anti-tumor effect on the two HVEM-positive tumor cell lines tested, opening the possibility to apply this therapy to a wide range of solid cancers where HVEM is over expressed (11) (12) (13) (14) (15) (34) (35) (36) (37) (38) (39) . The recent success of ICI for cancer immunotherapy (anti-CTLA-4, anti-PD-1/PD-L1) has confirmed the hypothesis that the immune system can control many cancers. In light of the promising results reported herein, anti-HVEM therapy might be combined with ICI to further enhance anti-tumor immunity.
Conclusions
Our study provides the first proof-of-concept that targeting HVEM is a new strategy for cancer immunotherapy. This is supported by data generated in humanized mice, carrying human tumors and human T cells, improving the relevance of our results relative to murine syngeneic models. 
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